Company intelligence / Profile preview
Angiogenix, Inc.
Burlingame, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Angiogenix is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. Their ACCLAIM™ product candidates are proprietary nitrates focused on replacing existing generic nitrate products. Their Vasotrophin® product is a novel angiogenic growth factor that stimulates both angiogenesis and arteriogenesis to produce new blood vessels.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small moleculesnitratesangiogenic growth factors
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Angiogenix, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiogenix, Inc..